PSCH - ETF AI Analysis
Top Page
Invesco S&P SmallCap Health Care ETF (PSCH)
PSCH, the Invesco S&P SmallCap Health Care ETF, has a solid overall rating driven largely by strong contributors like Alkermes, which brings robust profitability, low debt, and growth-focused acquisitions to the portfolio. Other key holdings such as Protagonist Therapeutics and Merit Medical Systems add to the fund’s appeal with healthy financial performance, though several positions face valuation concerns, profitability challenges, or bearish technical trends. The main risk factor is the ETF’s focused exposure to small-cap health care stocks, which can mean higher volatility and sensitivity to company-specific setbacks.
PSCH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 182.03M
- Region
- North America
- Expense Ratio
- 0.29%
- Beta
- 0.79
- Issuer
- Invesco
- Inception Date
- Apr 07, 2010
- Dividend Yield
- <0.01%
- Asset Class
- Equity
- Index Tracked
- S&P SmallCap 600 Capped Health Care Index - Benchmark TR Gross
PSCH Summary
The Invesco S&P SmallCap Health Care ETF (PSCH) follows the S&P SmallCap 600 Capped Health Care Index, focusing on smaller U.S. health care companies. It holds a mix of businesses in areas like drugs, biotech, medical devices, and health care services, including names such as Teleflex and Merit Medical Systems. Someone might invest in PSCH to seek growth from innovative, younger health care companies while spreading risk across many stocks in the sector. A key risk is that small health care stocks can be very volatile, so the ETF’s price can rise and fall sharply with changes in the market and health care news.
How much will it cost me?
This ETF has an expense ratio of 0.29%, which means you’ll pay about $2.90 per year for every $1,000 invested. That’s a bit higher than the average ETF because it focuses on a specific sector of small-cap health care stocks and is more specialized than broad, passively managed index funds.
What would affect this ETF?
PSCH could benefit if U.S. health care spending grows, new drug and device approvals increase, or supportive regulations and insurance coverage help small, innovative companies like its biotech and medical device holdings. On the downside, higher interest rates, tighter health care regulations or pricing pressures, and economic slowdowns that hurt smaller U.S. companies could make this small-cap health care ETF more volatile and limit future returns.
PSCH Top 10 Holdings
PSCH is essentially a small‑cap health care play, with U.S.-based biotech and medical device names steering the ship. Glaukos and Concentra are rising standouts, giving the fund a strong growth tilt, while Protagonist Therapeutics and TG Therapeutics add more fuel with steady-to-strong momentum despite some valuation and balance-sheet questions. On the flip side, PTC Therapeutics is clearly lagging and acts as a drag, and Teleflex’s mixed picture keeps it from fully pulling its weight. Overall, performance hinges on a concentrated cluster of nimble, higher-risk health care innovators.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 GKOS | Glaukos | 7.10% | $12.74M | $14.07B | 170.62% | 61Neutral |
 PTGX | Protagonist Therapeutics | 4.75% | $8.53M | $9.37B | 86.06% | 68Neutral |
 TGTX | TG Therapeutics | 4.40% | $7.89M | $9.36B | 79.84% | 65Neutral |
 ALKS | Alkermes | 3.85% | $6.92M | $7.61B | 47.11% | 80Outperform |
 LGND | Ligand Pharma | 3.26% | $5.85M | $6.43B | 72.54% | 60Neutral |
 TFX | Teleflex | 3.00% | $5.38M | $5.92B | 11.96% | 68Neutral |
 MMSI | Merit Medical Systems | 2.61% | $4.68M | $5.17B | 3.85% | 68Neutral |
 PTCT | PTC Therapeutics | 2.54% | $4.55M | $5.01B | -11.95% | 72Outperform |
 RDNT | Radnet | 2.64% | $4.73M | $5.78B | -3.43% | 63Neutral |
 CON | Concentra Group Holdings Parent, Inc. | 2.43% | $4.35M | $5.15B | 101.10% | 66Neutral |
PSCH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSCH, the sentiment is Positive. The current price of 55.69 is above the 20-day moving average (MA) of 53.25, above the 50-day MA of 53.53, and above the 200-day MA of 48.30, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 63.02 is Neutral, neither overbought nor oversold. The STOCH value of 88.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PSCH.
PSCH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| PSCH | $55.69 | $57.00(2.35% Upside) | $182.03M | 0.29% | 65Neutral |
 RSPH | $39.69 | $42.49(7.06% Upside) | $991.68M | 0.40% | 71Outperform |
 PJP | $130.54 | $159.11(21.88% Upside) | $575.09M | 0.58% | 70Neutral |
 XPH | $64.80 | $109.12(68.40% Upside) | $466.58M | 0.35% | 56Neutral |
 PINK | $40.62 | $50.42(24.12% Upside) | $335.60M | 0.51% | 65Neutral |
 PTH | $59.78 | $76.84(28.53% Upside) | $302.68M | 0.60% | 60Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PSCH | Invesco S&P SmallCap Health Care ETF | 55.69 | 13.32 | 31.44% | |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 39.69 | 9.65 | 32.11% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 130.54 | 34.57 | 36.02% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 64.80 | 15.34 | 31.00% | |
| PINK | Simplify Health Care ETF | 40.62 | 7.99 | 24.47% | |
| PTH | Invesco DWA Healthcare Momentum ETF | 59.78 | 13.14 | 28.17% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.